Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
País como asunto
Tipo del documento
Publication year range
1.
J Biomed Sci ; 27(1): 17, 2020 Jan 06.
Artículo en Inglés | MEDLINE | ID: mdl-31906961

RESUMEN

BACKGROUND: Influenza A viruses cause epidemics/severe pandemics that pose a great global health threat. Among eight viral RNA segments, the multiple functions of nucleoprotein (NP) play important roles in viral replication and transcription. METHODS: To understand how NP contributes to the virus evolution, we analyzed the NP gene of H3N2 viruses in Taiwan and 14,220 NP sequences collected from Influenza Research Database. The identified genetic variations were further analyzed by mini-genome assay, virus growth assay, viral RNA and protein expression as well as ferret model to analyze their impacts on viral replication properties. RESULTS: The NP genetic analysis by Taiwan and global sequences showed similar evolution pattern that the NP backbones changed through time accompanied with specific residue substitutions from 1999 to 2018. Other than the conserved residues, fifteen sporadic substitutions were observed in which the 31R, 377G and 450S showed higher frequency. We found 31R and 450S decreased polymerase activity while the dominant residues (31 K and 450G) had higher activity. The 31 K and 450G showed better viral translation and replication in vitro and in vivo. CONCLUSIONS: These findings indicated variations identified in evolution have roles in modulating viral replication in vitro and in vivo. This study demonstrates that the interaction between variations of NP during virus evolution deserves future attention.


Asunto(s)
Evolución Molecular , Variación Genética , Subtipo H3N2 del Virus de la Influenza A/fisiología , Biosíntesis de Proteínas/genética , Proteínas de Unión al ARN , Proteínas del Núcleo Viral , Replicación Viral/genética , Células A549 , Animales , Perros , Humanos , Gripe Humana/epidemiología , Gripe Humana/genética , Gripe Humana/metabolismo , Células de Riñón Canino Madin Darby , Proteínas de la Nucleocápside , Proteínas de Unión al ARN/biosíntesis , Proteínas de Unión al ARN/genética , Taiwán , Proteínas del Núcleo Viral/biosíntesis , Proteínas del Núcleo Viral/genética
2.
Biomed J ; 43(4): 375-387, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32611537

RESUMEN

BACKGROUND: Highly pathogenic emerging and re-emerging viruses continuously threaten lives worldwide. In order to provide prophylactic prevention from the emerging and re-emerging viruses, vaccine is suggested as the most efficient way to prevent individuals from the threat of viral infection. Nonetheless, the highly pathogenic viruses need to be handled in a high level of biosafety containment, which hinders vaccine development. To shorten the timeframe of vaccine development, the pseudovirus system has been widely applied to examine vaccine efficacy or immunogenicity in the emerging and re-emerging viruses. METHODS: We developed pseudovirus systems for emerging SARS coronavirus 2 (SARS-CoV-2) and re-emerging avian influenza virus H5 subtypes which can be handled in the biosafety level 2 facility. Through the generated pseudovirus of SARS-CoV-2 and avian influenza virus H5 subtypes, we successfully established a neutralization assay to quantify the neutralizing activity of antisera against the viruses. RESULTS: The result of re-emerging avian influenza virus H5Nx pseudoviruses provided valuable information for antigenic evolution and immunogenicity analysis in vaccine candidate selection. Together, our study assessed the potency of pseudovirus systems in vaccine efficacy, antigenic analysis, and immunogenicity in the vaccine development of emerging and re-emerging viruses. CONCLUSION: Instead of handling live highly pathogenic viruses in a high biosafety level facility, using pseudovirus systems would speed up the process of vaccine development to provide community protection against emerging and re-emerging viral diseases with high pathogenicity.


Asunto(s)
Betacoronavirus/efectos de los fármacos , Infecciones por Coronavirus/tratamiento farmacológico , Gripe Aviar/tratamiento farmacológico , Neumonía Viral/tratamiento farmacológico , Vacunas Virales , Animales , Betacoronavirus/inmunología , Betacoronavirus/patogenicidad , Aves , COVID-19 , Vacunas contra la COVID-19 , Infecciones por Coronavirus/prevención & control , Desarrollo de Medicamentos/métodos , Humanos , Virus de la Influenza A/inmunología , Gripe Aviar/prevención & control , Gripe Aviar/virología , Pandemias/prevención & control , Neumonía Viral/prevención & control , SARS-CoV-2
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda